A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Twist Bioscience Corp
TWST
$5.4B
Mkt Cap
$90.27
-2.35%
Twist Bioscience Corp (TWST) has a 5-year average return on invested capital (ROIC) of -29.4%. This is below average and may indicate limited pricing power.
Twist Bioscience Corp (TWST) has a market capitalization of $5.5B. It is classified as a mid-cap stock.
Twist Bioscience Corp (TWST) does not currently pay a regular dividend.
Twist Bioscience Corp (TWST) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Twist Bioscience Corp (TWST) reported annual revenue of $377 million in its most recent fiscal year, based on SEC EDGAR filings.
Twist Bioscience Corp (TWST) has a net profit margin of -20.6%. The company is currently unprofitable.
Twist Bioscience Corp (TWST) generated $-76 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
At Twist Bioscience Corporation, we work in service of our customers who are changing the world for the better. In fields such as health care, food/agriculture, industrial chemicals/materials and academic research, by using our products, our customers are developing ways to better lives and improve the sustainability of the planet. We believe Twist Bioscience is uniquely positioned to help accelerate their efforts and the faster our customers succeed, the better for all of us. We have developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. We have miniaturized traditional chemical DNA synthesis reactions to write over 1,000,000 pieces of DNA (oligonucleotides) up to 500 bases through direct synthesis on each silicon chip, approximately the size of a large mobile phone, reducing by 99.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 392M | 377M | 313M | 245M | 204M | 132M |
| Net Income | -77M | -78M | -209M | -205M | -218M | -152M |
| EPS | $-1.27 | $-1.30 | $-3.60 | $-3.60 | $-4.04 | $-3.15 |
| Free Cash Flow | -87M | -76M | -69M | -170M | -226M | -139M |
| ROIC | -38.9% | -16.2% | -44.2% | -32.8% | -27.6% | -26.1% |
| Gross Margin | 51.6% | 50.7% | 42.6% | 36.6% | 41.4% | 39.1% |
| Debt/Equity | 0.03 | 0.19 | 0.00 | 0.25 | 0.00 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -135M | -136M | -221M | -217M | -235M | -153M |
| Operating Margin | -34.4% | -36.2% | -70.6% | -88.6% | -115.3% | -115.4% |
| ROE | -16.8% | -16.4% | -44.2% | -32.8% | -27.6% | -26.2% |
| Shares Outstanding | 61M | 60M | 58M | 57M | 54M | 48M |
| Metric | 2017 | 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | N/A | N/A | 54M | 90M | 132M | 204M | 245M | 313M | 377M | 392M |
| Gross Margin | N/A | N/A | 12.8% | 31.8% | 39.1% | 41.4% | 36.6% | 42.6% | 50.7% | 51.6% |
| R&D | 19M | 20M | 36M | 43M | 69M | 120M | 107M | 91M | 80M | 76M |
| SG&A | 26M | 43M | 80M | 103M | 136M | 213M | 190M | 218M | 247M | 261M |
| EBIT | -58M | -71M | -109M | -140M | -153M | -235M | -217M | -221M | -136M | -135M |
| Op. Margin | N/A | N/A | -200.1% | -155.5% | -115.4% | -115.3% | -88.6% | -70.6% | -36.2% | -34.4% |
| Net Income | -59M | -71M | -108M | -140M | -152M | -218M | -205M | -209M | -78M | -77M |
| Net Margin | N/A | N/A | -198.0% | -155.3% | -114.9% | -107.0% | -83.5% | -66.7% | -20.6% | -19.6% |
| Non-Recurring | -507K | 0 | 0 | 0 | 0 | 0 | 16M | 45M | 49M | 49M |
| Returns on Capital | ||||||||||
| ROIC | N/M | -60.9% | -68.8% | -41.4% | -26.1% | -27.6% | -32.8% | -44.2% | -16.2% | -38.9% |
| ROE | N/A | N/A | -70.8% | -41.6% | -26.2% | -27.6% | -32.8% | -44.2% | -16.4% | -16.8% |
| ROA | -12330.6% | -61.5% | -57.6% | -35.1% | -21.7% | -22.7% | -26.4% | -34.0% | -12.4% | -12.0% |
| Cash Flow | ||||||||||
| Op. Cash Flow | -51M | -66M | -88M | -142M | -112M | -124M | -142M | -64M | -48M | -51M |
| Free Cash Flow | -58M | -70M | -103M | -152M | -139M | -226M | -170M | -69M | -76M | -87M |
| Owner Earnings | -58M | -75M | -105M | -166M | -159M | -221M | -202M | -146M | -137M | -141M |
| CapEx | 6.6M | 3.7M | 15M | 9.9M | 27M | 102M | 28M | 5.1M | 28M | 36M |
| Maint. CapEx | 5.0M | 5.7M | 6.1M | 6.7M | 9.8M | 17M | 29M | 31M | 25M | 25M |
| Growth CapEx | 1.6M | 0 | 8.6M | 3.2M | 17M | 85M | 0 | 0 | 3.2M | 11M |
| D&A | 5.0M | 5.7M | 6.1M | 6.7M | 9.8M | 17M | 29M | 31M | 25M | 25M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.9M | 3.0M | 11M | 17M | 37M | 80M | 30M | 51M | 64M | 66M |
| Debt Repayment | 4.2M | 0 | 2.5M | 3.3M | 3.3M | 1.6M | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||||
| Net Debt | -29M | -149M | -127M | -251M | -473M | -505M | N/A | -276M | -142M | -183M |
| Cash & Equiv. | 31M | 81M | 47M | 94M | 466M | 379M | 286M | 226M | 183M | 198M |
| Long-Term Debt | 2.2M | 7.2M | 4.4M | 1.4M | 1.6M | N/A | N/A | 0 | 15M | 15M |
| Debt/Equity | -0.02 | -0.06 | 0.07 | 0.12 | 0.01 | 0.00 | 0.25 | 0.00 | 0.19 | 0.03 |
| Interest Coverage | -64.6 | -53.7 | -84.1 | -178.0 | -416.1 | -2934.7 | -43431.8 | -7614.9 | N/A | N/A |
| Equity | -133M | -201M | 152M | 336M | 581M | 789M | 623M | 473M | 473M | 456M |
| Total Assets | 481K | 116M | 187M | 399M | 702M | 961M | 776M | 614M | 642M | 638M |
| Total Liabilities | 134M | 27M | 35M | 63M | 121M | 172M | 153M | 142M | 169M | 182M |
| Intangibles | N/A | 712K | 508K | 307K | 18M | 60M | 54M | 14M | 13M | 13M |
| Retained Earnings | N/A | -211M | -319M | -458M | -611M | -828M | -1.0B | -1.2B | -1.3B | -1.4B |
| Working Capital | N/A | 77M | 130M | 299M | 483M | 506M | 351M | 276M | 242M | 223M |
| Current Assets | 481K | 96M | 160M | 335M | 546M | 596M | 424M | 347M | 333M | 304M |
| Current Liabilities | N/A | 19M | 30M | 36M | 63M | 91M | 73M | 71M | 91M | 80M |
| Per Share Data | ||||||||||
| EPS | -24.49 | -25.51 | -3.92 | -3.57 | -3.15 | -4.04 | -3.60 | -3.60 | -1.30 | -1.27 |
| Owner EPS | -24.04 | -2.26 | -3.83 | -4.24 | -3.29 | -4.09 | -3.56 | -2.53 | -2.29 | -2.31 |
| Book Value | -55.07 | -6.08 | 5.54 | 8.58 | 12.03 | 14.64 | 10.97 | 8.15 | 7.92 | 7.44 |
| Cash Flow/Share | -21.18 | -2.00 | -3.20 | -3.63 | -2.32 | -2.31 | -2.51 | -1.11 | -0.80 | -0.85 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 2.4M | 33.1M | 27.5M | 39.2M | 48.3M | 53.9M | 56.8M | 58.0M | 59.7M | 61.3M |
| Valuation | ||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -71.1 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 4.3 | 8.7 | 8.6 | 2.6 | 1.9 | 5.7 | 3.4 | 12.1 |
| Price/Sales | N/A | N/A | 12.8 | 16.2 | 44.9 | 15.7 | 5.1 | 6.8 | 6.1 | 14.1 |
| FCF Yield | N/A | N/A | -15.8% | -5.2% | -2.8% | -11.1% | -14.6% | -2.6% | -4.7% | -1.6% |
| Market Cap | N/A | N/A | 652M | 2.9B | 5.0B | 2.0B | 1.2B | 2.7B | 1.6B | 5.5B |
| Avg. Price | N/A | N/A | 25.39 | 37.19 | 123.08 | 59.20 | 22.04 | 36.94 | 38.70 | 90.27 |
| Year-End Price | N/A | N/A | 23.72 | 75.02 | 104.00 | 37.79 | 20.56 | 46.39 | 26.91 | 90.27 |
Twist Bioscience Corp passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 42.1%.
Twist Bioscience Corp (TWST) has a debt-to-equity ratio of 0.19. This indicates a conservatively financed balance sheet.
Twist Bioscience Corp (TWST) reported earnings per share (EPS) of $-1.30 in its most recent fiscal year.
Twist Bioscience Corp (TWST) has a return on equity (ROE) of -16.4%. A negative ROE may indicate losses or negative equity.
Twist Bioscience Corp (TWST) has a 5-year average gross margin of 42.1%. This indicates decent pricing power.
The Ledger Terminal provides 9 years of financial data for Twist Bioscience Corp (TWST), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Twist Bioscience Corp (TWST) has a book value per share of $7.92, based on its most recent annual SEC filing.
No recent press releases.